Cargando…

Comparison of Clinico-Pathological Presentations of Triple-Negative versus Triple-Positive and HER2 Iraqi Breast Cancer Patients

BACKGROUND: Breast cancer remains the most common malignancy among the Iraqi population. Affected patients exhibit different clinical behaviours according to the molecular subtypes of the tumour. AIM: To identify the clinical and pathological presentations of the Iraqi breast cancer subtypes identif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alwan, Nada A. S., Tawfeeq, Furat N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Republic of Macedonia 2019
Materias:	Basic Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986522/ https://www.ncbi.nlm.nih.gov/pubmed/32010372 http://dx.doi.org/10.3889/oamjms.2019.808

Ejemplares similares

HER2 Positive Gastric Carcinomas and Their Clinico-Pathological Characteristics
por: Ognjenovic, Ljubomir, et al.
Publicado: (2018)

Chromogenic in Situ Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma
por: Ali, Ali Hussein Mohammed, et al.
Publicado: (2019)

Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients
por: Hadi, Ahmed Abdel, et al.
Publicado: (2016)

Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers
por: Altundag, Kadri
Publicado: (2017)

Clinico-pathological relationship between androgen receptor and tumour infiltrating lymphocytes in triple negative breast cancer
por: Elghazawy, Hagar, et al.
Publicado: (2021)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Vos, Hanne, et al.
Publicado: (2021)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

56371 The Signaling Axis of Tumor Suppressor LKB1 in Triple Negative Breast Cancer
por: Nguyen, Khoa, et al.
Publicado: (2021)

Nicotinic receptors modulate antitumor therapy response in triple negative breast cancer cells
por: Español, Alejandro, et al.
Publicado: (2022)

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
por: Li, Jie, et al.
Publicado: (2020)

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
por: Bartsch, Rupert
Publicado: (2021)

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
por: Machleidt, Anna, et al.
Publicado: (2013)

Roles of MALAT1 in development and migration of triple negative and Her-2 positive breast cancer
por: Xiping, Zhang, et al.
Publicado: (2017)

Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers
por: Bryan, Sarah, et al.
Publicado: (2021)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Clinico-Pathological Characteristics of Triple Negative and Non Triple Negative High Grade Breast Carcinomas with and Without Basal Marker (CK5/6 and EGFR) Expression at a Rural Tertiary Hospital in India
por: Choccalingam, Chidambharam, et al.
Publicado: (2012)

The Triple Queen and Her Hospital
por: Baron, J H
Publicado: (1996)

Dimensional Analysis of CD44(High) CD24(Low) and Ki67 in Triple Negative Breast Cancer
por: Tan, Betty, et al.
Publicado: (2019)

92418 Molecular imaging of the tumor microenvironment to predict response to combination treatment with immunotherapy in triple negative breast cancer
por: Napier, Tiara S., et al.
Publicado: (2021)

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
por: Domergue, Camille, et al.
Publicado: (2022)

Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer
por: Lu, Ming, et al.
Publicado: (2010)

Genomic Insights into Triple-Negative and HER2-Positive Breast Cancers Using Isogenic Model Systems
por: Mudvari, Prakriti, et al.
Publicado: (2013)

Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
por: Alanko, Johanna, et al.
Publicado: (2021)

Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response
por: Ciriaco, Nikaoly, et al.
Publicado: (2022)

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Investigating the clinical significance of EGFR expression using machine learning in a series of Iraqi patients with triple-negative breast cancer
por: Salman, Gufran, et al.
Publicado: (2022)

Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer
por: Bai, Fang, et al.
Publicado: (2020)

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer
por: Cao, Xu, et al.
Publicado: (2021)

4543 Glucocorticoid Receptors are essential effectors of TGFβ signaling in Triple Negative Breast Cancer
por: Kerkvliet, Carlos Jesus Perez, et al.
Publicado: (2020)

47982 Reversing the resistance to chemotherapy in White and Black patients with triple negative breast cancer (TNBC).
por: Gandhi, Shipra, et al.
Publicado: (2021)

Breast Cancer Among Iraqi Women: Preliminary Findings From a Regional Comparative Breast Cancer Research Project
por: Alwan, Nada A.S.
Publicado: (2016)

Association of HDAC8 Expression with Pathological Findings in Triple Negative and Non-Triple Negative Breast Cancer: Implications for Diagnosis
por: Menbari, Mohammad-Nazir, et al.
Publicado: (2020)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets
por: Gupta, Ishita, et al.
Publicado: (2020)

Establishment and characterization of novel highly aggressive HER2-positive and triple-negative breast cancer cell lines
por: Thongchot, Suyanee, et al.
Publicado: (2021)

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer
por: Yoder, Rachel, et al.
Publicado: (2022)

Outcomes of Women with Non-Metastatic Triple-Negative Breast Cancer in Oman: A single-centre experience
por: Kumar, Shiyam, et al.
Publicado: (2019)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021)

Acute Exercise Increases NK Cell Mitochondrial Respiration and Cytotoxicity against Triple-Negative Breast Cancer Cells under Hypoxic Conditions
por: CHO, EUNHAN, et al.
Publicado: (2023)

Histopathological Patterns and Outcomes of Triple-Positive Versus Triple-Negative Breast Cancer: A Retrospective Study at a Tertiary Cancer Center
por: Kadi, Mai S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vks9pn6qv0g17io79ck60s1ggl